In this article, we show that Omomyc, the only direct MYC inhibitor to reach a phase 2 clinical trial so far, can induce DDR defects and DNA damage in cancer cells and propose it as a cutting-edge therapeutic opportunity to overcome PARPi resistance. Here, MYC is linked to cancer.